| Literature DB >> 27287196 |
Zainul Amiruddin Zakaria1,2, Farhana Yahya3, Siti Syariah Mamat3, Nur Diyana Mahmood3, Nurhafizah Mohtarrudin4, Muhammad Taher5, Siti Selina Abdul Hamid6, Lay Kek Teh7, Mohd Zaki Salleh7.
Abstract
BACKGROUND: Methanol extract of Bauhinia purpurea L. (family Fabaceae) (MEBP) possesses high antioxidant and anti-inflammatory activities and recently reported to exert hepatoprotection against paracetamol (PCM)-induced liver injury in rats. In an attempt to identify the hepatoprotective bioactive compounds in MEBP, the extract was prepared in different partitions and subjected to the PCM-induced liver injury model in rats.Entities:
Keywords: Antioxidant; Bauhinia purpurea; Fabaceae; Flavonoids; Hepatoprotection; Synergistic action
Mesh:
Substances:
Year: 2016 PMID: 27287196 PMCID: PMC4902980 DOI: 10.1186/s12906-016-1110-4
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
PCM-induced hepatotoxicity treatment groups of the extracts
| Group | Extracts | Doses of extracts |
|---|---|---|
| I. | Normal control: 10 % DMSO, p.o | |
| II. | Negative control: 10 % DMSO, p.o | |
| Ill. | Positive control: 200 mg/kg silymarin, p.o | |
| IV. | PEBP | 50 mg/kg PEBP, p.o |
| V. | 250 mg/kg PEBP, p.o | |
| VI. | 500 mg/kg PEBP, p.o | |
| VlI. | EABP | 50 mg/kg EABP, p.o |
| VllI. | 250 mg/kg EABP, p.o | |
| IX. | 500 mg/kg EABP, p.o | |
| X. | AQBP | 50 mg/kg AQBP, p.o |
| XI. | 250 mg/kg AQBP, p.o | |
| XlI. | 500 mg/kg AQBP, p.o |
Total phenolic content of different extracts
| Sample | Total phenolic content (TPC) mg/100 g GAE |
|---|---|
| PEBP | 104.83 ± 1.64 |
| EABP | 270.27 ± 39.06 |
| AQBP | 132.08 ± 15.88 |
Total phenolic content are expressed as GAE (gallic acid equivalent)
All values are expressed as mean ± SEM
Superoxide scavenging activity of different extracts
| Sample | Superoxide scavenging (%) |
|---|---|
| PEBP | 62.20 ± 3.55 |
| EABP | 88.30 ± 5.25 |
| AQBP | 44.7 ± 3.15 |
The data are expressed as the percentage of free radical scavenging activity
All values are expressed as mean ± SEM
Note: H, high (71–100 %); M, moderate (41–70 %); L, low (0–40 %); NA, not active
Oxygen radical absorbance capacity of different extracts
| Sample | ORAC value (TE/100 g) |
|---|---|
| PEBP | 48,000 |
| EABP | 168,000 |
| AQBP | 172,000 |
The ORAC values are expressed in micromoles of Trolox Equivalents per 100 g of samples
Effect of extracts on the anti-inflammatory mediators using the in vitro lipoxygenase and xantine oxidase assays
| Sample | Lipoxygenase (%) | Xanthine oxidase (%) |
|---|---|---|
| NDGA (reference standard of LOX) | 99.86 ± 0.14 | - |
| Allopurinol (reference standard of XO) | - | 97.58 ± 0.32 |
| PEBP | NA | 8.57 ± 0.86 |
| EABP | 15.05 ± 2.33 | 17.05 ± 3.14 |
| AQBP | 9.65 ± 1.10 | 1.65 ± 0.84 |
All values are expressed as mean ± SEM
Note: H, high (71–100 %); M, moderate (41–70 %); L, low (0–40 %); NA, not active
Effect of PEBP, EABP and AQBP on percentage change of liver weight in PCM- treated rats
| Treatment | Dose (mg/kg) | Change of body weight (%) | Liver/body weight ratio (g/100 g) |
|---|---|---|---|
| Normal control | - | 5.14 ± 0.43 | 2.86 ± 0.05 |
| 10 % DMSO + PCM | 17.58 ± 2.10a | 4.58 ± 0.33a | |
| Silymarin + PCM | 200 | 3.11 ± 0.67b | 3.59 ± 0.10b |
| PEBP + PCM | 50 | 14.20 ± 1.64 | 4.24 ± 0.14 |
| 250 | 14.69 ± 2.60 | 4.20 ± 0.32 | |
| 500 | 15.84 ± 1.34 | 3.82 ± 0.05a | |
| EABP + PCM | 50 | 15.20 ± 1.07 | 4.53 ± 0.32 |
| 250 |
| 4.62 ± 0.17 | |
| 500 |
| 3.95 ± 0.19a | |
| AQBP + PCM | 50 |
| 4.16 ± 0.11 |
| 250 |
| 4.39 ± 0.21 | |
| 500 | 14.26 ± 1.76 | 4.18 ± 0.25 |
Values are expressed as means ± S.E.M. of six replicates
a Significant different (p < 0.05) when compared to the normal control group ((10 % DMSO + dH2O)-treated) of the respective column
b Significant different (p < 0.05) when compared to the negative control group ((10 % DMSO + PCM)-treated) of the respective column
Fig. 1a Normal liver parenchyma, b Section of liver tissue treated with 3 g/kg PCM (p.o) showing massive necrosis, and inflammation. c Section of liver tissue pre-treated with 200 mg/kg silymarin followed by PCM showing preservation of normal hepatocytes. d Section of liver tissue pre-treated with 50 mg/kg PEBP followed by PCM showing massive tissue necrosis and mild inflammation. e Section of liver tissue pre-treated with 250 mg/kg PEBP followed by PCM showing moderate necrosis and mild inflammation. f Section of liver tissue pre-treated with 500 mg/kg PEBP followed by PCM showing moderate necrosis and inflammation. g Section of liver tissue pre-treated with 50 mg/kg EABP followed by PCM showing moderate necrosis. h Section of liver tissue pre-treated with 250 mg/kg EABP followed by PCM showing mild necrosis. i Section of liver tissue pre-treated with 500 mg/kg EABP followed by PCM showing mild inflammation and necrosis. j Section of liver tissue pre-treated with 50 mg/kg AQBP followed by PCM showing moderate inflammation and necrosis. k Section of liver tissue pre-treated with 250 mg/kg AQBP followed by PCM showing mild necrosis and inflammation. l Section of liver tissue pre-treated with 500 mg/kg AQBP followed by PCM showing mild inflammation. (H & E, X100). CV) central vein. N) necrosis. I) inflammation
Effect of PEBP, EABP and AQBP on liver function enzymes, ALT, AST and ALP
| Treatment | Dose (mg/kg) | ALT (U/L) | AST (U/L) | ALP (U/L) |
|---|---|---|---|---|
| Normal control | - | 13.1 ± 1.0 | 89.6 ± 2.5 | 110.0 ± 6.4 |
| 10 % DMSO + PCM | 1797.0 ± 141.2a | 2970.0 ± 254.0a | 338.8 ± 50.7a | |
| Silymarin + PCM | 200 | 517.5 ± 181.1b | 535.5 ± 98.8b | 201.0 ± 11.8b |
| PEBP + PCM | 50 | 1844.0 ± 105.1 | 2158.0 ± 126.8b | 371.4 ± 38.9 |
| 250 | 1831.0 ± 199.0 | 1960.0 ± 131.1b | 316.0 ± 30.5 | |
| 500 | 1219.0 ± 150.5b | 1558.0 ± 74.7b | 308.2 ± 20.4 | |
| EABP + PCM | 50 | 1036 .0 ± 155.2b | 1846.0 ± 189.9b | 340.4 ± 58.4 |
| 250 | 519.7 ± 143.4b | 1807.0 ± 233.3b | 320.0 ± 25.9 | |
| 500 | 543.9 ± 184.1b | 895.8 ± 238.0b | 256.0 ± 36.9 | |
| AQBP + PCM | 50 | 1777.0 ± 119.0 | 2930.0 ± 151.1 | 338.2 ± 34.0 |
| 250 | 1338.0 ± 147.2b | 2017.0 ± 262.1b | 329.2 ± 29.2 | |
| 500 | 719.3 ± 90.9b | 1243.0 ± 190.2b | 317.6 ± 31.0 |
Values are expressed as means ± S.E.M. of six replicates
a Significant different (p < 0.05) when compared to the normal control group ((10 % DMSO + dH2O)-treated) of the respective column
b Significant different (p < 0.05) when compared to the negative control group ((10 % DMSO + PCM)-treated) of the respective column
Effect of PEBP, EABP and AQBP on total protein (TP; g/dL) and LDH (U/L) levels
| Treatment | Dose (mg/kg) | TP (g/dL) | LDH (U/L) |
|---|---|---|---|
| Normal control | - | 64.1 ± 3.8 | 408.2 ± 60.6 |
| 10 % DMSO + PCM | 50.4 ± 1.4a | 1454.0 ± 255.0a | |
| Silymarin + PCM | 200 | 69.1 ± 2.1b | 462.0 ± 59.8b |
| PEBP + PCM | 50 | 77.5 ± 3.5b | 1065.0 ± 127.3 |
| 250 | 65.3 ± 1.4b | 371.0 ± 35.7b | |
| 500 | 76.5 ± 2.9b | 702.4 ± 90.7b | |
| EABP + PCM | 50 | 88.1 ± 4.1b | 765.0 ± 199.9b |
| 250 | 66.9 ± 0.9b | 415.0 ± 103.0b | |
| 500 | 83.9 ± 2.3b | 727.8 ± 130.8b | |
| AQBP + PCM | 50 | 68.9 ± 3.8b | 689.2 ± 148.8b |
| 250 | 70.4 ± 2.0b | 905.4 ± 65.2b | |
| 500 | 68.2 ± 1.9b | 525.2 ± 33.9b |
Values are expressed as means ± S.E.M. of six replicates
aSignificant different (p < 0.05) when compared to the normal control group ((10 % DMSO + dH2O)-treated) of the respective column
bSignificant different (p < 0.05) when compared to the negative control group ((dH2O + PCM)-treated) of the respective column
Phytochemical constituents of PEBP, EABP and AQBP in comparison to the leaves of B. purpurea (BP) and MEBP
| Classes of bioactive compounds | Types of extracts | ||||
|---|---|---|---|---|---|
| BP | MEBP | PEBP | EABP | AQBP | |
| Alkaloids | - | - | - | - | - |
| Saponins | + | + | - | + | + |
| Flavonoids | + | + | ++ | ++ | - |
| Tannins and polyphenolic compounds | + | + | + | + | + |
| Triterpenes | +++ | + | ++ | - | - |
| Steroids | +++ | ++ | +++ | +++ | - |
BP - B. purpurea leaves, MEBP - methanol extract of B. purpurea
For saponins - + = 1–2 cm froth; ++ = 2–3 cm froth; +++ = >3 cm froth
For flavonoids, tannins, triterpenes and steroids - + = weak colour; ++ = mild colour; +++ = strong colour
For akalioids - + = negligible amount of precipitate; ++ = mild precipitate; +++ = strong precipitate; – = not detected
Fig. 2The UV spectra analysis of peak 1 (RT = 26.85 min) and peak 2 (RT = 29.4 min) of the PEBP at 254 nm and 339 nm exhibiting the λ max at 273 nm and 323 nm respectively
Fig. 3The UV spectra analysis of peak 3 (RT = 17.93 min), peak 4 (RT = 19.20 min) and peak 5 (RT = 19.83 min) of the EABP at 366 nm exhibiting the λ max at 256–353 nm, 265–343 nm and 254–351 nm, respectively, suggesting, in part, the presence of flavonoid-based compounds
Fig. 4The UV spectra analysis of peak 1 (RT = 7.75 min), peak 2 (RT = 3.69 min), and peak 4 (RT = 17.89 min) and peak 7 (RT = 19.83 min) of the AQBP at 210 nm, 254 nm, and 366 nm respectively. The peaks exhibit the λ max at 251–330 nm, 271–354 nm, 256–349 nm and 254–349 nm, respectively, suggesting, in part, the presence of flavonoid-based compounds
Histopathological evaluation of the effects of PEBP, EABP and AQBP against PCM-induced hepatic injury in rats
| Treatment | Dose (mg/kg) | Steatosis | Necrosis | Inflammation | Haemorrhage |
|---|---|---|---|---|---|
| Normal control | - | - | - | - | - |
| 10 % DMSO + PCM | - | +++ | ++ | + | |
| Silymarin + PCM | 200 | - | + | + | - |
| PEBP + PCM | 50 | - | +++ | ++ | - |
| 250 | - | ++ | ++ | - | |
| 500 | - | ++ | ++ | - | |
| EABP + PCM | 50 | - | ++ | ++ | - |
| 250 | - | + | + | - | |
| 500 | - | + | + | - | |
| AQBP + PCM | 50 | - | ++ | ++ | - |
| 250 | - | + | ++ | - | |
| 500 | - | + | ++ | - |
The severity of various features of hepatic injury was evaluated based on those following scoring scheme: − normal, + mild effect, ++ moderate effect, +++ severe effect